Mereo Biopharma Group Plc(DE:MAH0)
€0.26+0.01 (+2.34%)
DE:MAH0
Mereo Biopharma Group Plc stock drug pipeline
€0.26
At close:+0.01 (+2.34%)
Mereo Biopharma Group Plc (MAH0) Drug Pipeline
1 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Setrusumab | Osteogenesis Imperfecta | Phase II | Terminated | Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta | Mar 28, 2022 | ― |
| Setrusumab | Osteogenesis Imperfecta | phase2AndPhase3 | Active Not Recruiting | Setrusumab vs Placebo for Osteogenesis Imperfecta | Nov 08, 2021 | ― |
| Nivolumab, Etigilimab | Metastatic Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult | phase1AndPhase2 | Completed | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | Feb 12, 2021 | ― |
| Alvelestat Oral Tablet - Dose 1, Alvelestat Oral Tablet - Dose 2 | Copd, Emphysema, Alpha 1-Antitrypsin Deficiency | Phase II | Completed | A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. | Jun 20, 2018 | ― |
| Bct197, Itraconazole 200 Mg | Interaction | Phase I | Completed | The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants | Apr 06, 2018 | ― |
| Bps804 | Osteogenesis Imperfecta | Phase II | Withdrawn | An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta | Jul 12, 2017 | ― |
| Vitamin D, Calcium, Setrusumab, Zoledronic Acid (Optional) | Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type Iii, Osteogenesis Imperfecta Type Iv | Phase II | Completed | A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 | Apr 03, 2017 | ― |
| Bct197, Azithromycin | Interaction | Phase I | Completed | The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers | Sep 28, 2016 | ― |
| Bgs649 | Hypogonadotropic Hypogonadism | Phase II | Completed | A 6 Month Safety Extension Study of MBGS205 | Sep 12, 2016 | ― |
| Bgs649 | Hypogonadotropic Hypogonadism | Phase II | Completed | Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism | Mar 17, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Setrusumab | Phase II | Osteogenesis Imperfecta | Terminated | Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta | Mar 28, 2022 | ― |
| Setrusumab | phase2AndPhase3 | Osteogenesis Imperfecta | Active Not Recruiting | Setrusumab vs Placebo for Osteogenesis Imperfecta | Nov 08, 2021 | ― |
| Nivolumab, Etigilimab | phase1AndPhase2 | Metastatic Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult | Completed | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | Feb 12, 2021 | ― |
| Alvelestat Oral Tablet - Dose 1, Alvelestat Oral Tablet - Dose 2 | Phase II | Copd, Emphysema, Alpha 1-Antitrypsin Deficiency | Completed | A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. | Jun 20, 2018 | ― |
| Bct197, Itraconazole 200 Mg | Phase I | Interaction | Completed | The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants | Apr 06, 2018 | ― |
| Bps804 | Phase II | Osteogenesis Imperfecta | Withdrawn | An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta | Jul 12, 2017 | ― |
| Vitamin D, Calcium, Setrusumab, Zoledronic Acid (Optional) | Phase II | Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type Iii, Osteogenesis Imperfecta Type Iv | Completed | A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 | Apr 03, 2017 | ― |
| Bct197, Azithromycin | Phase I | Interaction | Completed | The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers | Sep 28, 2016 | ― |
| Bgs649 | Phase II | Hypogonadotropic Hypogonadism | Completed | A 6 Month Safety Extension Study of MBGS205 | Sep 12, 2016 | ― |
| Bgs649 | Phase II | Hypogonadotropic Hypogonadism | Completed | Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism | Mar 17, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mereo Biopharma (DE:MAH0) have in its pipeline
Mereo Biopharma Group Plc DE:MAH0 is currently developing the following drugs: Setrusumab, Nivolumab, Etigilimab, Alvelestat Oral Tablet - Dose 1, Alvelestat Oral Tablet - Dose 2, Bct197, Itraconazole 200 Mg, Bps804, Vitamin D, Calcium, Setrusumab, Zoledronic Acid (Optional), Bct197, Azithromycin, Bgs649, Bct197, Bps804 20Mg/Kg, Bct197 Part A, Bct197 Part B, Prednisone, Bct197, Investigational New Drug Company Code: Bgs649, Active Treatment With A High Dose Of Bgs649, Active Treatment With A Low Dose Of Bgs649. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
